MDVL(Delisted)
MedAvail Holdings·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MDVL
Medavail Holdings, Inc.
A technology-enabled pharmacy organization that provides turnkey in-clinic pharmacy services and home delivery operations
4720 East Cotton Gin Loop, Suite 220, Phoenix, Arizona, 85040
--
MedAvail Holdings, Inc., was incorporated in Nevada on April 11, 2007. In February 2011, the company acquired its dietary supplement platform called MYO-T12 product. In February 2011, the company's main business activities were focused on the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies designed to maintain or improve health and muscle tissue performance. The company is developing a marketing and sales strategy to maximize the revenue of MYO-T12 in the body builder and fitness user consumption base as well as broader age range targets. In addition, the company is evaluating the value of this product in the market for treatments including sarcopenia, cachexia, anorexia, obesity and muscle-related conditions.
Company Financials
EPS
MDVL has released its 2023 Q2 earnings. EPS was reported at -3.06, versus the expected 0, missing expectations. The chart below visualizes how MDVL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MDVL has released its 2023 Q2 earnings report, with revenue of 405.00K, reflecting a YoY change of -25.41%, and net profit of -5.79M, showing a YoY change of 50.58%. The Sankey diagram below clearly presents MDVL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
